Drug-conjugated monoclonal antibodies in advanced/metastatic breast cancer
The goal of this report is to analyze, in a general way, the structure and mechanism of action of drug-conjugated monoclonal (ADC) and examine the studies that led their approval in advanced/metastatic breast cancer (ABC). PubMed, Scopus and SciELO databases were used between 2000 and 2022; Bibliogr...
| Authors: | ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2023 |
| Country: | Perú |
| Institution: | FIHU |
| Repository: | Diagnóstico |
| Language: | Spanish |
| OAI Identifier: | oai:revistadiagnostico.fihu.org.pe:article/427 |
| Online Access: | https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/427 |
| Access Level: | Open access |
| Keyword: | Anticuerpos monoclonales inmunoconjugados cáncer de mama citostáticos Antibody drug conjugates antibodies monoclonal breast cancer cytostatic agents |
| Summary: | The goal of this report is to analyze, in a general way, the structure and mechanism of action of drug-conjugated monoclonal (ADC) and examine the studies that led their approval in advanced/metastatic breast cancer (ABC). PubMed, Scopus and SciELO databases were used between 2000 and 2022; Bibliographic references were searched for the keywords associated with ADC and ABC. ADCs combine classical monoclonal assays with a linker and a cytotoxic payload to destroy cancer cells in a targeted manner, when there is internalization of the corresponding receptor. There are currently three ACDs that have been approved for the treatment of CMAM; studies that have demonstrated significant advantages in progression-free survival when compared to standard treatment; evaluation of its main adverse events; implications for its management in our everyday lives; and potential inclusion in the current treatment of CMAM. |
|---|